Published price vs quote-only
Shed vs Novi: Which One Publishes Its Price? (2026)
Compare Shed and Novi on real cost over 12 months, medication type, price stability and support. Independent 2026 analysis, no first-month gimmicks.
Published · Pricing as published in our provider dataset, synced · Editorial scores 9.9 and 7.0 out of 10
We may receive compensation when you click partner links. Rankings are based on research methodology, not sponsorship.
Both Shed and Novi will get a GLP-1 prescription to your door without an in-person visit. The question is what the year after that first shipment looks like.
One of these programs can be evaluated before you start it and one cannot. Novi lists Semaglutide from $133/mo, tirzepatide from $166/mo; with Shed, Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment.
What follows is a like-for-like read of both programs: entry pricing, maintenance pricing, formulary, support model and the terms attached to each. Gaps in a provider's disclosure are reported as gaps, because they are part of what you are buying.
The short answer
- Easier to price in advance
- Novi — Semaglutide from $133/mo, tirzepatide from $166/mo. The other side quotes after intake, so a like-for-like total is not available before you apply.
- FDA-approved medication
- Shed — The only side that can write an approved brand-name product at all — it offers name-brand FDA-approved GLP-1 and compounded GLP-1.
- Tirzepatide access
- Novi — Tirzepatide at $166/mo; the other side publishes semaglutide only.
- Most support included
- Shed — Continuous coaching built into every treatment plan.
Shed and Novi, side by side
Every figure below is the provider's own published number. The blank spaces are theirs, not ours.
| Shed | Novi | |
|---|---|---|
| Advertised price | 10% off the first month, price quoted after intake | Semaglutide from $133/mo, tirzepatide from $166/mo |
| Rate after promotions | not published before intake | $133/mo |
| Pricing structure | Quoted only after intake | Published rate per medication |
| Medication | Name-brand FDA-approved GLP-1 and compounded GLP-1 | Compounded semaglutide and compounded tirzepatide |
| Price transparency | Quote only, after intake | Published upfront |
| State coverage | Not published | Not published |
| How fast you start | 2-minute approval assessment | Online intake |
| Membership fee | Not stated | None |
| Payment options | Card only, no financing published | Card only, no financing published |
| Patient reviews | 8,500 | 50,124 |
| eRxDoctor score | 9.9/10 | 7.0/10 |
What Shed and Novi actually cost over a year
Trial data runs to 68 and 72 weeks; the pricing people compare runs to 30 days. The figures underneath convert both offers into what you will have spent by month six and month twelve.
| Shed | Novi | |
|---|---|---|
| First month | Not published | $133 |
| Months 2 onward | Not published | $133/mo |
| 6-month total | Not computable | $798 |
| 12-month total | Not computable | $1,596 |
| Best published plan | No multi-month discount published | No multi-month discount published |
A like-for-like annual total is not available for Shed: Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment. Treat any comparison that quotes one as an estimate someone else has made for you.
One publishes a price. One does not.
Novi states its terms upfront: Semaglutide from $133/mo, tirzepatide from $166/mo, published rate per medication. You can decide whether it fits your budget without giving anyone a medical history.
Shed inverts that: Shed does not publish standard pricing; you receive a personalized quote after completing the intake assessment. Personalization is a real justification, but the result is a quote delivered at the point you have already invested time in the process.
If you do go through Shed's intake, ask for the month-two price in writing before you pay for month one. That single question resolves most of the disclosure gap.
Inside the Shed program
Shed offers both name-brand and compounded GLP-1 weight loss medications with integrated coaching, a 2-minute approval assessment, and 10% off your first month. In this pairing, its distinguishing feature is one of the few platforms that will write either a name-brand or a compounded GLP-1, with coaching bundled into the plan rather than sold beside it.
Intake is 2-minute approval assessment. Fulfillment is home delivery after clinician review. The commercial terms are quoted only after intake, quote only, after intake.
Behind the prescription sits continuous coaching built into every treatment plan. Available medication: name-brand FDA-approved GLP-1 and compounded GLP-1.
Shed pros
- Continuous coaching is integrated into treatment, not just a prescription
- Offers both FDA-approved name-brand GLP-1 and compounded options on one platform
- 10% off your first month for new patients
- Fast 2-minute approval assessment
Shed cons
- Standard pricing is not published, you receive a personalized quote after intake
- Coaching-bundled model can cost more than bare-prescription platforms
- Name-brand options carry significantly higher costs than compounded alternatives
Set beside Novi, the thing to weigh: you cannot know what you will pay until you have finished the intake.
A closer look at Novi
The pitch is the narrowest gap here between semaglutide and tirzepatide pricing, at $133 and $166. $200 OFF - GLP-1 for $133 Today
Practically: online intake, free 2-day shipping with every order, and a pricing model that is published rate per medication.
No long-term contract, cancel anytime. The formulary covers compounded semaglutide and compounded tirzepatide.
Novi pros
- No insurance required and no long-term contract, cancel anytime
- $200 off promotion brings GLP-1 to $133 today
- Largest patient base on this list, 50,000+ patients, signaling operational maturity
- Competitive pricing: semaglutide from $133/month and tirzepatide from $166/month
Novi cons
- Tirzepatide ($166) costs more than the semaglutide entry rate
- Compounded medication only, no branded Ozempic, Wegovy, or Zepbound
- No published outcome or weight loss guarantee
Where it gives ground to Shed: the $133 rate depends on a $200-off promotion and there is no outcome guarantee.
Picking between them
Choose Shed if:
- you want continuous coaching built into every treatment plan rather than a prescription alone
- you want an FDA-approved finished medication rather than a compounded preparation
- the level of clinical contact suits you: continuous coaching built into every treatment plan
- the feature you would actually use: one of the few platforms that will write either a name-brand or a compounded GLP-1, with coaching bundled into the plan rather than sold beside it
Choose Novi if:
- you want to start on their timeline: online intake
- the level of clinical contact suits you: no long-term contract, cancel anytime
- delivery works the way you want it to: free 2-day shipping with every order
- you would rather use the platform with the longer public record (50,124 reviews)
Honest trade-offs
On price. Only Novi publishes a rate you can plan against (Semaglutide from $133/mo, tirzepatide from $166/mo). The other quotes after intake, which is a cost of a different kind: you cannot budget the year in advance.
On commitment. Neither publishes a multi-month discount, so both are month-to-month decisions and neither asks you to prepay for a response you have not had yet. Neither publishes financing options, so plan for the full amount each month.
On predictability. Quoted only after intake at Shed, against published rate per medication at Novi. The more predictable structure is worth a premium to anyone who has been surprised by a telehealth invoice before.
On access. Shed advertises 2-minute approval assessment and home delivery after clinician review; Novi advertises online intake and free 2-day shipping with every order. Neither publishes its state coverage, so confirm you are eligible before paying for anything.
Evidence and regulatory status
Both platforms sell access to the same drug class, so the clinical record below applies equally to each.
The FDA approved tirzepatide for chronic weight management in November 2023, two years after semaglutide, per FDA.
In the STEP 1 trial, weekly semaglutide 2.4 mg produced a mean body-weight change of −14.9% at 68 weeks against −2.4% on placebo, per NEJM, STEP 1.
None of that settles which of these two to use. It does mean the drug is doing the work, and you are choosing who supplies it and on what terms.
Shed vs Novi: common questions
Does Shed or Novi offer tirzepatide?
Novi does, at $166/mo. Shed publishes name-brand FDA-approved GLP-1 and compounded GLP-1 only, so moving to tirzepatide would mean moving provider — a new intake, a new price, and the loss of any rate you had locked in.
Do Shed and Novi prescribe the same medication?
No. Shed dispenses both name-brand FDA-approved medication and compounded alternatives; Novi dispenses compounded medication prepared by a pharmacy rather than manufactured under an approved application. That is a regulatory difference rather than a branding one, and it is the main reason the two prices are not directly comparable.
Is Shed or Novi better for a first GLP-1 prescription?
First-timers usually get more from clinical access than from a lower rate, because the first two months are where most people stop. On that basis Shed has the stronger case; after month three, cost should take over.
Can I switch from Shed to Novi later?
You can, and people do — usually when an introductory price expires. Budget for a repeat intake and a short overlap in supply, and confirm what happens to any unused portion of a multi-month plan before you cancel it.
Are Shed and Novi legitimate?
Both are licensed telehealth platforms that route a prescription through a clinician review before anything is dispensed; neither sells medication without one. Shed operates on quoted only after intake with pricing quote only, after intake, Novi on published rate per medication, published upfront. The meaningful due diligence is on the medication category and the terms, not on whether the platforms are real.
The verdict
Neither of these two publishes enough for a clean cost verdict, which is itself the finding. Shed leads on one of the few platforms that will write either a name-brand or a compounded GLP-1, with coaching bundled into the plan rather than sold beside it; Novi leads on the narrowest gap here between semaglutide and tirzepatide pricing, at $133 and $166.
Before choosing either, get the maintenance-dose price in writing. Without it, any comparison — including this one — is working with half the information.
Whichever you choose, diarise the month the introductory pricing ends and re-run the comparison then. Neither platform will remind you.
Keep comparing
- Shed vs HersPublished price vs quote-only
- Shed vs TrimRxPublished price vs quote-only
- Gala vs NoviBudget vs premium
- Refills vs NoviLarge platform vs smaller platform
- Directmeds vs Mochi HealthPublished price vs quote-only
- Directmeds vs IVIM HealthPublished price vs quote-only
See every provider in context on the weight loss rankings, or browse the full comparison index.
Disclaimers and methodology
Medical content is informational only and does not replace professional diagnosis, treatment, or emergency care.
Some links are affiliate links and may generate commission at no extra cost to you.
Pricing reflects what each provider published as of the sync date above and changes frequently; confirm the current rate, and the rate at your maintenance dose, before you pay. Six- and twelve-month totals are calculated from those published rates and exclude anything a provider bills separately.
eRxDoctor is an independent publisher. It is not a medical provider, is not affiliated with or endorsed by Shed or Novi, and does not sell treatment. Read our ranking methodology.